WCN26-3855 SGLT2 Inhibitors Ameliorate Adiposopathy and Inflammation in Diabetic and Non-Diabetic CKD

Read full text Summarise with VIRAT
Authors: Luis D’Marco, Owahabanun-Joshua Okojie, Nelia Steib, Oscar Arias, Pilar Salvador, Fortea Isabel, Ana Checa-Ros
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This study assessed differences in adiposopathy and inflammatory biomarkers between type 2 diabetes (T2DM) and non-diabetic patients across chronic kidney disease (CKD) stages and investigated adipose tissue pathways for SGLT2 inhibitor (SGLT2i) renoprotection.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Adipokines Inflammation and Metabolic Diseases Diabetes Treatment and Management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104612–104612
Publication date
25 March 2026
Language
EN